Free press releases distribution network?

Agency / Source: HitGen Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



HitGen and Viva Biotech Establish Strategic Alliance - HitGen and Viva Biotech announce a strategic alliance- the two companies will collaborate to provide a fully-integrated drug discovery service, with the partnership focusing on early hit to lead generation, accelerating client drug discovery projects
HitGen and Viva Biotech Establish Strategic Alliance

 

PRZOOM - /newswire/ - Chengdu, Sichuan, China, 2012/12/23 - HitGen and Viva Biotech announce a strategic alliance- the two companies will collaborate to provide a fully-integrated drug discovery service, with the partnership focusing on early hit to lead generation, accelerating client drug discovery projects.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

HitGen Ltd, a rapidly developing lead generation services company to the global biopharmaceutical industry, and Viva Biotech Ltd, a well established and internationally known leading company in structure-based drug discovery services, today announced they have entered into a strategic alliance. Under the terms of the agreement, HitGen and Viva Biotech will collaborate to provide a fully-integrated drug discovery services, with collaboration focus on early hit to lead generation, to accelerate their clients’ drug discovery projects from targets into early development. Hit identification is a notable missing piece in preclinical drug discovery capability in China and this alliance is expected to fulfill.

Dr Jin Li, Chairman and Chief Executive Offer at HitGen said,“We are pleased to have formed a strategic alliance with Viva Biotech. Over the past 5 years, they have established a reputation for high-quality preparation and characterization of a large number of potential recombinant drug targets, assay development and structure-based drug discovery. HitGen is a rapidly developing lead generation company with world class library and strong capabilities in in vitro biology, medicinal and synthetic chemistry and computational sciences. In a very short period of time, using encoded library technology, we have established sizeable small molecule compound libraries and the associated screening platform for hit and lead generation. By effective combination of the expertise and experience from the strategic partnership and working closely together with our customers, who will be experts in their particular therapeutic project field, we expect to provide clear added value to their projects and help to provide accelerated project progression. My colleagues and I are looking forward to working with the Viva Biotech team to offer an outstanding fully-integrated drug discovery research services to our customers.”

Commenting on the partnership, Dr Cheney Mao, Viva Biotech’s CEO said,“HitGen has set up and rapidly made a large high quality encoded library for hit or tool compound identification which is a capability unavailable to date in China. Viva Biotech is working on several hundred potential drug targets for several dozen major pharmaceutical companies every year and there are a large number of targets which would need selective lead or tool compounds for target validation and drug discovery. At Viva Biotech, we strongly believe that collaborations between specialist companies can deliver enhanced value to customers. By working with HitGen, we will be able to offer our existing and new customers the opportunities to access HitGen’s large chemical libraries and screening capabilities. Coupling this with Viva’s established scientific capabilities in recombinant protein production, structural biology and preclinical capabilities, we believe the alliance will maximize strengths from both companies to offer our customers accelerated services from targets to candidate drugs.”

HitGen Ltd is a life science company based in Chengdu, China. We are an innovation-driven and customer-focused company. HitGen aims to establish a unique platform and associated capabilities for drug discovery research.With a focus on hit identification and lead generation during the early phase of drug discovery R&D, we have our core capabilities in medicinal chemistry, chemical library design and synthesis, in vitro screening and selection. Employing 70 scientists, HitGen has built a core platform for progressing projects from targets to the leads stage, including high quality and large compound libraries (encoded and discrete), screening and selection, and informatics analysis and design.

Based in Shanghai, China Viva Biotech is one of the few biology-focused CROs providing preclinical drug discovery research services. Viva is privately owned and financed by leading investors in the US. It currently employs close to 200 scientists at a 65,000 sq. ft. research center. The center is equipped with state-of-the-art instruments housed by modern laboratories in an artistically designed building. Viva now works with all of the top ten largest global pharmaceutical companies and dozens of small to medium sized US and Europe-based businesses in studies of gene-to-structure, in vitro and in vivo assays, target ID, ADME, animal models, and more.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: HitGen Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


HitGen and Viva Biotech Establish Strategic Alliance

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Michael Li - HitGen.com 
+86(0)28 85197385 enquiries[.]hitgen.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any HitGen Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From HitGen Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  S&A Capital Partner Ltd

Visit  BizJobs.com

Visit  Intrinsic Executive Search Ltd







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today